Index to Volume 151

Author Index

Abou-Zeid, C., 170
Abramson, J. S., 370, 854
Acar, J. F., 501
Ackerman, J. A., 743
Aeppli, D., 362
Ajdukiewicz, A. B., 187
Akhtar, Q., 194
Albrecht, J. K., 731
Albritton, W. L., 840
Alexander, E. R., 1034
Ali, S., 194
Alpert, G., 737
Alward, W. L. M., 599, 604
Ambrosino, D. M., 1174
Anacker, R. L., 1052
Andersen, R. D., 449
Anderson, D. C., 217
Anderson, L. J., 626
Anderson, P., 869
Anthony, B. F., 221
Arap-Siongok, T. K., 750
Arbus, G. S., 775
Archer, G. L., 243
Arita, K., 742
Armstrong, D., 523, 711
Aronsson, B., 476
Arrobio, J. O., 437
Arvin, A. M., 756
Arya, S. C., 569
Askelof, P., 646
Ater, J. L., 966
Atkins, E., 570
Austin, E., 823
Auzepy, P., 969
Babcock, G. F., 555
Babiuk, L. A., 937
Babu, S., 854
Bagley, A., 948
Bailey, A., 966
Bailowitz, A., 372
Baker, C. J., 217
Baker-Zander, S. A., 264
Bakker-Woudenberg, I. A. J. M., 917
Baltimore, R. S., 589
Banatvala, J. E., 89
Band, J., 971
Barton, R. P., 1012
Basolo, F., 1100
Battaglia, M., 796
Bayer, A. S., 157
Bean, B., 362
Bender, T. R., 599, 604
Bendinelli, M., 1100
Bennett, J. E., 565
Bentivegna, M., 377
Bergdoll, M. S., 883
Berghash, S. T., 494
Berman, J. D., 698
Bernard, E. M., 523, 711
Berry, L. J., 337
Best, J. M., 89
Betts, R. F., 744
Betz, T. G., 367
Bielefeldt Ohmann, H., 937
Bigley, R. H., 42
Black, C M., 929
Black, F. L., 850
Black, J. R., 650
Black, W. J., 650
Blackmore, C. A., 840
Blaser, M. J., 227
Bodey, G. P., 704
Bodicky, C. J., 741
Bombí, J. A., 566
Bommer, J., 374
Bonin, P., 264
Boose, D., 1123
Borchert, M., 682
Botsford, K. B., 209
Bottone, E. J., 179
Bouma, B. N., 1019
Bowen, S., 1144
Boyce, W. T., 1034
Bozdech, M. J., 1167
Bradsher, R. W., 57
Brander, E., 832
Brandt, C. D., 437
Bréchot, C., 610
Brewster, F. E., 1109
Broitman, S. A., 148
Broome, C. V., 1144
Brotman, B., 618
Brown, V. A., 195
Bryan, C. S., 563
Bryan, L. E., 581
Bryson, Y. L., 746
Buck, J., 367
Bunter, J. W., 376
Burke, D. S., 1093
Butler, T., 1138
Byron, K. S., 1109
Caine, V. A., 344
Caldwell, H. D., 1037
Callahan, L. T., 375
Campbell, C. R., 741
Cancellieri, V., 482
Cannon, J. G., 650
Cantey, J. R., 766
Caredda, F., 925
Carson, J. L., 181
Catto, B. A., 1130
Chaicumpa, W., 124
Chandler, S. H., 344
Chang, R. S., 459
Channon, J. Y., 750
Chanock, R. M., 634
Chantavibul, S., 1093
Chantler, J. K., 330
Chapman, A. J., Jr., 878
Cheeseman, S. H., 772
Cheever, A., 1166
Chesney, P. J., 883
Chin, J., 772
Chu, M. C., 1157
Chung, W. K., 280
Clarridge, J. E., 878
Cocito, C., 170
Coello, J., 259
Cohen, M. L., 716
Coleman, R. M., 929
Collatz, E., 501
Collier, A. M., 181
Collins, M. S., 1171
Conaldi, P. G., 1100
Concepcion, K. F., 221
Concepcion, N. F., 221
Convit, J., 9
Cordano, A. M., 551
Corey, L., 344
Couroucé, A. M., 610
Cowart, R. E., 721
Cox, J. E., 1034
Crass, B. A., 883
Crowe, S., 365
Cryz, S., J., Jr., 665
Cunningham, A. L., 638
Cushing, A. H., 114
Daha, M. R., 1019
Dall, L., 153
Damsker, B., 179
d'Arminio Monforte, A., 925
Davis, J. P., 883, 1144
Debord, T., 976
De Cock, K. M., 750
Del Busto, R., 567
Deinhardt, F., 374
Dennis, J., 376
Densen, P., 33
De Sousa, M. A., 963
de Vries, R. P., 9
Dewlett, H. J., 367
Dickinson, V., 823
Dietrick, D. R., 243
Di Leo, R., 377
Dillon, H. C., Jr., 1073
DiSalvo, A. F., 563
DiVincenzo, C., 166
Domingue, G. J., 995

Dorsey, J. H., 1171
D'Ottone, K., 551
Douglas, R. G., Jr., 744
Douglas, R. M., 731
Dreesman, G. R., 761
Duke-Duncan, P. M., 953
du Moulin, G. C., 148
Duncanson, F. P., 748
Dunny, G. M., 494
DuPont, H. L., 471
Eardley, D. D., 514
Echeverria, P., 124
Edmond, B. J., 106
Edwards, M. S., 217
Eickhoff, T. C., 383
Eidson, M., 716
El Kholy, A., 320
Elliott, L. B., 367
Ellison, R. T., III, 1123
Ellner, J. J., 320
Entringer, M. A., 449
Erb, P., 739
Ericsson, C. D., 471
Eskola, J., 444
Evatt, B. L., 559
Fainstein, V., 704
Fara, G. M., 482
Fennell, C. L., 131
Feorino, P. M., 559
Fernie, B. F., 626
Ferrieri, P., 672
Fick, R. B., Jr., 589
Fikrig, S., 1045
Filice, G. A., 47
Finch, M. J., 956
Fisher, E. J., 567
Fleming, P. C., 775
Fling, M. E., 783
Flournoy, N., 325
Forland, M., 508
Foster, B. G., 721
Fox, J. G., 743
Francis, D. P., 559, 599, 604
Frank, A. L., 73, 948
Frazer, J. R. E., 638
Freedman, L. R., 973
Freter, R., 355
Frick, P. G., 902
Friedman, H. M., 737
Fukumi, H., 81
Fürer, E., 665
Gajdusek, D. C., 691
Gallalee, J. V., 698
Gallin, J. I., 563
Gander, R. M., 508
Gandy, S. L., 1061
Gardella, S., 566
Gardner, M. K., 437
Geiseler, P. J., 195
Germanier, R., 665
Gerna, G., 796
Gershon, H., 541
Gibb, G. N., 1034
Gibbs, C. J., Jr., 691
Gigliotti, F., 1005
Gillenius, P., 646
Gillis, J. M., 544
Givner, L. B., 217
Glass, R. I., 236
Glew, R. H., 23
Glode, M. P., 1174
Gmelin, K., 374
Gnehm, H. E., 273
Gold, J. W. M., 523
Goldstein, F. W., 501
Goldstein, L. C., 325
Gonzales, N. M., 9
Gorbach, S. L., 960
Gori, Z., 1100
Govindarajan, S., 192
Granström, G., 646
Granström, M., 646
Gray, B. M., 1073
Grayston, J. T., 832
Greenberg, H. B., 99
Greenblatt, H. C., 911
Greenwood, J. R., 840
Guerrant, R. L., 804, 963
Gust, I. D., 365
Gutmann, L., 501
Guze, L. B., 973
Guze, P. A., 973
Hackman, R. C., 325
Hadchouel, M., 610
Hadfield, T. L., 790
Hadley, W. K., 153
Hall, D. B., 599, 604
Hammer, S. M., 544
Hammerschlag, M. R., 1045
Hammond, G. W., 1153
Hampton, K. D., 854
Handsfield, H. H., 264, 344
Hanna, B. A., 295
Hanrahan, J. P., 1144
Hara, M., 81
Harboe, M., 170
Hargrett, N. T., 716
Harrison, A. K., 559
Harrison, C. J., 301
Harrison, H. R., 1034
Hayes, S. F., 1052
Hays, P. L., 369
Hedley-Whyte, J., 148
Hendry, R. M., 626
Hengstler, B., 535, 859
Henle, G., 1150
Henle, W., 1150
Henshaw, N. G., 181
Herrman, K. L., 772
Hersh, E. M., 704
Hewlett, D., Jr., 748
Hewlett, E. L., 804
Heyward, W. L., 599, 604
Hickman, R. K., 514, 1158
Hierholzer, J. C., 626
Hightower, A. W., 1144
Hilleman, M. R., 407
Hodgen, A. N., 750
Hoefs, J., 192
Hoekstra, J. B. L., 974
Hofman, F. M., 314
Holmes, K. K., 131
Holmgren, J., 236
Honda, T., 742
Hook, E. W., 264
Hopfer, R., 704
Hopkins, J. D., 783
Horan, P. K., 308
Horsley, R., 1144
Horswood, R. L., 634
Horwitz, C. A., 1150
Hoxie, J., 737
Huda, S., 236
Hughey, D., 749
Huima, T., 618
Humphrey, C. D., 485
Huq, M. I., 236
Hurwitz, E. S., 772
Igarashi, Y., 287
Iglewski, B. H., 42
Ingham, H. R., 569
Inokuchi, S., 153
Inzana, T. J., 869
Ishida, K., 973
Jackson, G. G., 1170
Jacobs, R. F., 57
James, J. F., 1157
Jayanetra, P., 551
Jeffries, B. C., 437
Jimenéz-Lucho, V. E., 567
Johnson, I., 1153
Johnson, K. P., 337
Johnson, P. C., 471
Johnson, R. H., 314
Johnston, J. L., 243
Johnston, L. I., 963
Jones, J. C., 548
Jones, J. M., 1167
Jones, L. A., 953
Jones, T. C., 739
Jonsson, S., 878
Juliano, R. L., 704
Kabins, S. A., 209
Kabir, S., 194
Kallick, C. A., 203
Kalmanson, G. M., 973
Kalter, E. S., 1019
Kalyanaraman, V. S., 559
Kanai, K., 287
Kapikian, A. Z., 99
Kaplan, J. E., 568
Karasic, R. B., 273
Karmali, M. A., 775

Kaslow, R. A., 372
Kass, E. H., 1158
Katich, M., 971
Kawashima, Y., 287
Kazanjian, P. H., 15
Keating, M., 704
Kendrick, M., 1158
Kennedy, R. C., 761
Kern, E. R., 1116
Kettyls, G. D., 330
Khan, M. R., 236
Khatib, R., 186
Khayam-Bashi, H., 528
Kim, H. W., 437
Kim, S. M., 280
Kinney, J. S., 772
Kitzis, M.-D., 501
Kleeman, K., 823
Kleemola, M., 832
Koenig, D. W., 634
Kohler, P. F., 227
Kommerell, B., 374
Kopecko, D., 551
Korlath, J. A., 568
Kretzer, F. L., 682
Kumar, M. L., 772
Kunin, C. M., 388
Kuritsky, J. N., 568
LaForce, F. M., 1123
Lam, K., 157
Laorakpongse, T., 1093
Larke, R. P. B., 330
Larson, T., 746
La Scolea, L. J., Jr., 1162
Latts, E., 1150
Law, B. J., 988
Lee, C. J., 658
Lee, H. Y., 280
Lee, I. J., 280
Lee, S.-C., 1081
Le Guellec, A., 976
Lehmann, N. I., 365
Lehrer, R. I., 890
Leibowitz, R. E., 295
Lenox, T., 748
Lentino, J. R., 1170
Levin, D., 541
Levin, S., 196, 745
Levine, J. F., 295
Levine, M. M., 551
Levy, M. E., 716
Lewis, C., 437
Lewis, D. E., 555
Liaw, Y.-F., 1081
Lim, C., 775
Limpakarnjanarat, K., 840
Lininger, L., 1166
Lior, H., 775
List, R. H., 1052
Liu, H., 859
Ljungh, Å, 972
Locarnini, S. A., 365
Lochner, J. E., 42
Lohiya, G., 192
Lokerse, A. F., 917
Lopez-Berestein, G., 704
Lucas, C. R., 365
Lucas, S. B., 750
Lue, Y., 748
Lukehart, S. A., 264
Luna, M., 704
Lydick, E., 375, 749
Lynch, S. E., 148
Maayan, S., 748
MacCormack, J. N., 823
McCrorie, M., 365
MacDonald, K. L., 716
McDougall, J. K., 344
Macher, A. M., 563
McIntosh, K., 626
McKendall, R. R., 464
McKendrick, G. D., 372
McKenzie, R., 970
McLean, A. A., 375
McMahon, B. J., 599, 604
McManus, E. J., 1167
Maeda, W., 192
Maki, S., 742
Mann, R. E., 1052
Mansueto, S., 377
Marcon, M. J., 854
Marks, M. I., 988
Marmer, D. J., 57
Martin, M. L., 559
Maslow, M. J., 295
Mathewson, J. J., 471
Matsushita, K., 287
Matteucci, D., 1100
Mayer, K. H., 783
Maynard, J. E., 599
Medeiros, E., 344
Mehta, K., 704
Mehta, R., 704
Melish, M. E., 1157
Mendelman, P. M., 1061
Mendizabal-Morris, C. A., 850
Meroni, B., 925
Meurman, O., 444
Meyers, J. D., 325, 344
Meyran, M., 976
Michel, M. F., 917
Miles, A. J., 437
Miles, H. B., 731
Miller, R. H., 1081
Miller, S. N., 748
Mills, J., 153
Mills, J. T., 1158
Mizuno, S. I., 742
Modlin, R. L., 314
Mogan, K. A., 1012
Möllby, R., 476
Monson, M. H., 790
Montag, D. M., 485
Moore, B. W., 731
Moran, D. M., 1166
Moreau, N., 501
Morgan, D. R., 471
Moroni, M., 925
Mosquera, J. A., 259
Mowatani, T., 742
Mufson, M. A., 749
Muñoz, J., 566
Murphy, B. R., 744
Murphy, C. F., 804
Murray, B. E., 551
Musher, D. M., 682, 878
Myers, M. G., 106
Myerson, D., 325
Nahmias, A. J., 929
Naito, H., 81
Nakamura, T., 691
Naot, Y., 541
Nash, T., 1166
Nath, S., 1138
Nathan, C. R., 209
Natiyar, V. N., 259
Neva, F., 1166
Newcomer, C. E., 743
Nisalak, A., 1093
Nishida, M., 287
Nomdedeu, B., 566
Nord, C.-E., 476
Norden, C. W., 291
Noto, H., 287
Novelli, V. M., 372
Nwankwo, M. U., 23
O'Brien, R. T., 966
O'Brien, T. F., 783
Ogra, P. L., 1162
Onorato, I. M., 772
Origitano, T. C., 166
Osburn, B. I., 337
O'Shea, S., 89
Oshiro, L. S., 376
Osman, G. S., 320
Osterholm, M. T., 568, 1144
Overall, J. C., Jr., 966, 1116
Pachucki, C. T., 1170
Palmer, D. L., 378
Palmer, E. L., 559
Pan-Urae, R., 551
Parenti, D. M., 140
Parrott, R. H., 437
Parsonnet, J., 514, 1158
Pass, R. F., 772
Passarani, N., 796
Payne, N. R., 672
Pelton, S. I., 273
Pennington, J. E., 15
Perine, P. L., 131
Perla, E., 748
Perlino, C. A., 378
Perrillo, R. P., 741

Pesanti, E. L., 454
Peter, G., 981
Petrak, R. M., 196
Petric, M., 775
Philip, R. N., 823
Phillips, D. J., 929
Pier, G. B., 514, 575
Pittman, F. E., 485
Plotkin, S. A., 737
Poindexter, N. J., 65
Pollack, M. S., 1
Pollock, A. A., 295
Pomerantz, S., 459
Pottage, J. C., Jr., 196
Potter, T. A., 911
Potts, B. J., 337
Preblud, S. R., 737
Prenzel, I., 551
Prince, A. M., 280, 618
Prince, G. A., 634
Pritchard, D. G., 1073
Puck, J. M., 555
Puhakka, H., 444
Puhr, N. D., 716
Puig de la Bellacasa, J., 566
Pulliam, L., 153
Pumarola, A., 566
Rahal, J. J., Jr., 295
Rahman, H., 1138
Ramsey, R. B., 559
Rapp, F., 349
Rastetter, M., 325
Ravdin, J. I., 804, 816
Rawlings, J. A., 367
Re, T., 925
Rea, T. H., 314
Read, R., 731
Rees, P. H., 750
Reeves, W. C., 99
Regts, D., 917
Reichman, M., 166
Reichman, O. H., 166
Reimer, C. B., 929
Ressel, S. J., 548
Reuben, J., 704
Reynolds, H. Y., 589
Rice, P. A., 273
Rice, T. W., 203
Rich, R. R., 1, 555
Richard, C., 969
Rigau-Perez, J. G., 840
Riley, L. W., 956
Rimailho, A., 969
Riou, B., 969
Roberts, N. J., Jr., 308
Robinson, W. S., 1081
Robinson, W. A., 449
Rocklin, R. E., 320
Rodriguez, W. J., 437
Rodríguez-Iturbe, B., 259
Rodriques, A., 748
Roerdink, F. H., 917
Roggendorf, M., 374
Rondanelli, E. G., 796
Rosales, S. B., 1162
Rosenblum, M. G., 704
Rosenstreich, D. L., 911
Ross, S. C., 33
Rossi, E., 925
Rothman, S. W., 960
Roue, R., 976
Rowe, B., 124
Roy, S. K., 1138
Rozman, C., 566
Ruben, F. L., 845
Rudnick, H., 1150
Rusanen, E., 820
Ruuskanen, O., 444
Ryder, R. W., 99, 187
Sabin, A. B., 420
Sack, R. B., 99
Saikku, P., 832
Sakulramrung, R., 995
Salata, R. A., 804, 816
Sale, G. E., 325
Sande, M. A., 528, 1028
Sanders, C. C., 399
Sanders, G. E., 741
Sanders, W. E., Jr., 399
Sarkkinen, H., 444
Schaefler, S., 295
Schaffner, A., 902
Schlievert, P. M., 65
Schlipköter, U., 374
Schmid, G. P., 1144
Schnarr, D., 186
Schonberger, L. B., 772
Schoolnik, G. K., 895
Schuit, K. E., 23
Schulzer, M., 330
Scotto, J., 610
Segal, G. P., 314, 890
Selsted, M. E., 890
Seriwatana, J., 124
Shanley, J. D., 454
Sheagren, J. N., 355
Shekar, R., 203
Shenep, J. L., 1005, 1012
Shepherd, W. M., 89
Sherertz, R. J., 252
Sherman, R., 166
Shimizu, M., 287
Shinners, E., 291
Shulman, H. M., 325
Siber, G. R., 1174
Simberkoff, M. S., 295
Singh, N., 99
Sisson, P. R., 569
Smart, J., 114
Smith, A. L., 1061
Smith, P. F., 227
Snydman, D. R., 140
Sonigo, P., 610
Sonoguchi, T., 81
Speelman, P., 1138
Spika, J. S., 370
Spriggs, D. R., 753, 978, 1175
Squier, S. U., 589
Stagno, S., 772
Stallings, E. P., 437
Stamm, W. E., 131
Stanberry, L. R., 106
Starr, S. E., 737
Steere, A. C., 1144
Stevens, D. A., 895
Stewart, J. A., 772
Stoll, B. J., 1138
Stolz, S. J., 883
Stone, Y., 626
Storch, G. A., 741
Stringer, M. F., 974
Strohmeyer, C., 716
Sugar, A. M., 895
Sullivan, J. L., 1091
Sullivan, M. L., 252
Sullivan, M. P., 704
Sumaya, C. V., 984
Sun, H. S., 280
Sundsten, B., 170
Sundharalingam, K., 1045
Svennerholm, A.-M., 236
Syriopoulou, V. P., 1061
Taber, L. H., 73, 948
Takahashi, K., 287
Takehiro, A., 287
Takeuchi, Y., 81
Tanner, W. B., 367
Tauber, M. G., 528
Taylor, B., 367
Taylor, C. R., 314
Taylor, D. N., 124
Taylor, J. P., 367
ten Cate, J. W., 1019
Tenover, F. C., 131
Tenser, R. B., 548
Theilmann, L., 374
Thomas, E. D., 325
Thomas, L. A., 1052
Thomas, V. L., 508
Thompson, H., 459
Thompson, K., 166
Thorne, G. M., 960
Thornton, S. A., 471
Tingle, A. J., 330
Tiollais, P., 610
Tirapat, C., 124
Todd, W. J., 1037
Tomasz, A., 535, 859
Toniolo, A., 1100
Totten, P. A., 131
Townsend, J. W., 57
Tringali, G., 377
Trumpp, C. E., 273

Tsai, Y.-C., 1158
Tsuo, C., 626
Tuazon, C. U., 565, 1166
Tulloch, S., 187
Tuomanen, E., 535, 859
Turner, L., 823
Tweardy, D. J., 320
Uhrin, M., 845
Ulmer, W. C., 57
Ussery, M. A., 1093
Valinluck, B., 192
van Eden, W., 9
Van Kessel, L. J. P., 974
van Rood, J. J., 9
Varela, L. R., 850
Venezio, F. R., 166
Verbrugh, H. A., 974
Vergeau, B., 976
Vergeront, J. M., 883
Verhoef, J., 1019
Verma, M. R., 1153
Virolainen, E., 444
Vitale, G., 377
Vogt, R. L., 976
Wachsmuth, I. K., 790
Wachsmuth, K., 716
Wadström, T., 972
Wain-Hobson, S., 610
Wallace, R. J., Jr., 878
Walley, M. S., 314
Wand, P. J ., 883
Waner, J. L., 301
Wang, S.-P., 832, 1034
Wang, Z., 658
Ward, J. I., 1061
Washburn, R. G., 563, 565
Wasilauskas, B. L., 854
Webster, L. T., Jr., 1130
Weibel, R. E., 737
Weikel, C. S., 963
Weinstein, R. A., 209
Weisfeld, J. S., 1144
Welliver, R. C., 1162
Wells, J. G., 716
Wells, J. M., 73
Wezenberg, J. M., 131
White, K. E., 568
Whitley, R. J., 971
Whittle, H. C., 187
Wilfert, C. M., 823
Williams, C. A., 741
Williams, C. L., 1174
Williams, S. C., 929
Williamson, R., 501
Wilson, C., 320
Wilson, K. H., 355
Wilson, W., 153
Wilson, W. R., 1028
Winter, S. M., 523
Wong, B., 711
Wood, L. V., 471
Woodhour, A. F., 375
Woods, D. E., 581
Woodward, A. J., 731
Wormser, G. P., 748
Worswick, D. A., 731
Wrzos, H., 349
Xiao, S.-H., 1130
Yaeger, A. S., 772, 953
Yanagihara, R., 691
Yeh, T.-J., 966
Yeo, M. J., 372
Yoo, J. Y., 280
Young, E. J., 682
Yow, M. D., 948
Yvonnet, B., 187
Zak, O., 535, 859, 1028
Zampini, L., 925
Zar, F., 195
Zierdt, C. H., 203

Subject Index

AIDS
- asymptomatic intestinal carriage of cryptosporidium in patients, 195
- detection of two human T cell viruses in the lymphocytes of a hemophiliac, 559
- disproportionate expansion of a minor subset of T cells in patients, 555
- humoral response of patients to disseminated infection with *M. avium–M. intracellulare*, 523
- *M. avium–M. intracellulare* in the intestinal tracts of patients, 179
- phagocytic and fungicidal activity of monocytes, 565
- ultrastructural association of *P. carinii* in rat lung, 181

Acinetobacter calcoaceticus, infection in burn patients due to contamination of mattresses, 252

Acyclovir
- high-dose iv, adverse effects in treatment of ambulatory patients with herpes zoster, 362
- high-dose oral, for immunosuppressed children at risk for disseminated herpesvirus infections, 372
- topical, on herpes simplex lesions of immunocompromised patients, 970, 971

Adenoviruses, and pediatric gastroenteritis, 437

Adherence lectin, inhibitable, of *E. histolytica*
- associated with mitogenic activity, 816
- purification and relation to amoebic virulence in vitro, 804

Aeromonas hydrophila, as an enteropathogen, 972

Amantidine use, in the USA, 1977–1982, 372

Amikacin resistance, in gram-negative bacilli, correlation with use of drug, 295

Amphotericin B
- liposomal, for treatment of systemic fungal infections in patients with cancer, 704
- prophylaxis of disseminated aspergillosis, effect of ketaconazole, 902

Ampicillin
- and corticosteroids, effects of CSF characteristics in experimental pneumococcal meningitis, 528
- free and liposome-entrapped, for treatment of infection with *L. monocytogenes* in mice, 917
- resistance, plasmid-mediated in *H. influenzae* type b isolates from Alaska, 1061

Anaerobic culture, the hamster gastrointestinal tract as a model of a continuous flow culture, 355

Annual meeting presentations
- history of development and use of oral poliovirus vaccine, 420
- implications of microbial resistance to new beta-lactam antibiotics, 399
- responsibility for optional use of antimicrobial agents, 388
- the social evolution of the IDSA, 383
- vaccine development and use, new directions, 407

Antibacterial defenses, isolation of an antibacterial peptide from human lung lavage fluid, 1123

Antibiotic class, role in rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis, 1012

Antibiotic cross-resistance associated with changes in outer membrane proteins of *Enterobacter, Klebsiella*, and *Serratia*, 501

Antibiotic resistance
- multiple drug-resistant *S. enteritidis* outbreak in Liberia, 790
- of gram-negative bacilli to amikacin, 295
- transmissible gentamicin resistance in coagulase-negative staphylococci in a cardiac surgery unit, 243

Antibiotic therapy failure, persistence of *N. meningitidis* after iv therapy, 370

Antibodies
- monoclonal, characterization of protective action against *R. rickettsii* in mice, 1052
- neutralizing, to pertussis toxin in whooping cough, 646
- to lipopolysaccharide, action on *H. influenzae* type b, mediated by a serum factor, 869
- to *R. rickettsii*, prevalence in an area endemic for Rocky Mountain spotted fever, 823
- to rubella, class-specific, in the serum and nasopharyngeal washings of vaccinees, 89
- to *V. cholerae* O1 in Bangladesh, seroepidemiological study, 236
- to *T. pallidum*, in human infection, 264

Antibody effectiveness in experimental infection with HSV type 1, IgG-mediated viral clearance, 464

Antibody response
- antiserum to a *E. coli* J5 mutant, protection against sublethal infection, 995
- polyclonal, to 14-valent pneumococcal vaccine in the elderly, 845
- titers of tetanus antitoxin in diverse populations of women of childbearing age, 850
- to 23-valent pneumococcal polysaccharide vaccine, 749
- to *C. jejuni* purified antigen, 742
- to core glycolipid of *E. coli* strain J5, related to age, 988
- to Epstein-Barr virus, assessed serologically at long-term follow-up, 1150
- to group B *Streptococcus* type II, 1074
- to *H. influenzae* type B capsular polysaccharide combined with *B. pertussis*, 1173
- to HSV, IgG subclass antibodies, 929
- to infection with *B. catarrhalis*, 878
- to Japanese encephalitis virus, kinetics in human serum and CSF, 1093
- to *N. asteroides*, mediated by two immunodominant antigens, 895
- to pneumococcal type 19F polysaccharide, increased by klebsiella polysaccharide, 658
- to toxic-shock-syndrome toxin, 883

Antigenic analysis of RSV, 626, 634

Antimicrobial agents
- and *C. difficile* in acute enteric disease, epidemiology in Sweden, 1980–1982, 476
- and resistance in Enterobacteriaceae, spread by a single plasmid, 783
- responsibility for optional use, 388

Antiviral drugs, synergistic effect against HSV in microtiter plate assay, 1116

Arabinitol, stereoisomeric configurations in serum, urine, and tissues in invasive candidiasis, 711

Arthritis, chronic, explanation for presence of rubella virus in

peripheral joints, 638
Aspergillosis, disseminated, effect of ketaconazole on amphotericin B prophylaxis, 902
Aspergillus fumigatus, causing external otitis in an immunocompromised patient, 196

Bacterial endocarditis, in rats with experimental enterococcal pyelonephritis, 973
Bacterial shock, activation and inhibition of Hageman factor–dependent pathways and the complement system, 1019
Bactericidal effects of photoradiation therapy with hematoporphyrin derivative, 166
Beta-lactam antibiotics, new, implications of microbial resistance, 399
Beta-lactam resistance phenotype, multiple, emergence in group B *Streptococcus* of bovine origin, 494
Blastomyces dermatitidis, phagocytosis by monocyte-derived macrophages from different hosts, 57
Bone marrow cells, in transference of genetic control of resistance to trypanosomiasis in mice, 911
Bone marrow transplant recipient, fatal fungemia with arthritic involvement caused by *T. beigelii*, 566
Border disease virus, infection, consequences to the CNS of congenital infection in sheep, 337
Bordetella pertussis
  combined with capsular polysaccharide of *H. influenzae* type B, antibody response in infants, 1174
  patients infected with, presence of neutralizing antibodies to pertussis toxin, 646
Botryomycosis, visceral, caused by *N. mucosa* in a patient with chronic granulomatous disease, 563
Boutonneuse fever, acute, persistence of antibodies to *R. conorii*, 377
Bovine herpesvirus–1, effect on immunologic functions in calves with viral-bacterial pneumonia, 937
Branhamella catarrhalis infection, development of bactericidal antibody, 878
Brucella species, phagocytosis and killing by human PMNLs, 682
Burkitt's lymphoma, EBC and oncogenes as co-factors in disease, 978
Burn patients, infection due to *A. calcoaceticus* by way of contamination of mattresses, 252

C-reactive protein levels in CSF as differentiation of meningitis from other CNS diseases, 854
Calcium channel–blocking drugs, influence on the microbicidal function of human neutrophils, 15
Campylobacter
  infections
    first year of national surveillance, 956
    in homosexual men, isolation of two new species of the organism, 131
  isolates, susceptibility to bactericidal effects of human serum, 227
Campylobacter cinaedi (sp. nov.), associated with enteric disease in homosexual men, 131
Campylobacter fennelliae (sp. nov.), associated with enteric disease in homosexual men, 131
Campylobacter fetus, resistance to the bactericidal effects of human serum, 227
Campylobacter jejuni
  experimental infection of hamsters, 485
  isolated from a rectal biopsy specimen, 976
  prevalence in random-source cats used in the biomedical research, 743
  purified antigen, appearance of antibodies in sera and relation to bacterium-excreting period, 742
  susceptibility to the bactericidal effects of human serum, 227
Candida tropicalis, determination of stereoisomeric forms of arabinitol as an aid to diagnosis, 711
Candidiasis, invasive, stereoisomeric configuration of arabinitol in serum, urine, and tissues, 711
Cannulae wounds, local infections associated with transparent dressings, 971
Capnocytophaga species, infection in normal patients and immunocompromised hosts, 140
Cell-mediated immunity
  against Hantaan virus infection in infant mice, 691
  in CM infection in children, 301
  mitogenic activity of an inhibitable adherence lectin on *E. histolytica*, 816
Central nervous system diseases, differentiation of meningitis by determination of C-reactive protein in CSF, 854
Central nervous system, abnormalities after congenital infection of sheep with border disease virus, 337
Chancroid, outbreak in California, epidemiology and control measures, 840
Chemiluminescence, luminol-dependent of human leukocytes, effect of *C. trachomatis* and requirements for opsonization, 1045
Chlamydia psittaci, causing an epidemic of mild pneumonia, 832
Chlamydia trachomatis
  effect on luminol-dependent chemiluminescence of human leukocytes and requirements for opsonization, 1045
  immunotype J, infection associated with trachoma in a previously endemic area, 1034
  ultrastructural studies of interaction with host cells, 1037
Chlamydial release, from HeLa 229 cells, ultrastructural studies, 1037
Cholera, El Tor, seroepidemiological studies in Bangladesh, 236
Ciprofloxacin vs. tobramycin as therapy for experimental osteomyelitis caused by *P. aeruginosa*, 291
Clostridium difficile
  and antimicrobial agents in acute enteric disease: epidemiology in Sweden, 1980–1982, 476
  population dynamics in the gastrointestinal tract of hamsters, 355
Clostridium perfringens, toxigenic type A, associated with necrotizing enteritis, 974
Coccidioides immitis
  defective T cell response in disseminated infection, 314
  in vitro effect of cationic peptides from granulocytes, 890
Coccidioidomycosis, disseminated, localization of T cells in situ, 314
Colitis associated with antibiotics, model in hamster infection with *C. difficile*, 355
Colorado tick fever
  as a human model of virus-induced leukopenia, 449
  circulating interferon and clinical symptoms, 966

Complement system, activation and inhibition in uncomplicated bacteremia or bacterial shock, 1019
Coronaviruses, human enteric, antigenic relatedness to human coronavirus OC43 and possible role in gastroenteritis, 796
Corticosteroids, and ampicillin, effects on CSF characteristics in experimental pneumococcal meningitis, 528
Corynebacteria, cross-reaction of cytoplasm and cell-wall antigens with those of mycobacterium, 170
Coxsackie B3 virus, causing systemic lymphoid atrophy in mice, effects of virus and immunopotentiating agents, 1100
Coxsackie B4 virus, nosocomial infection in two chronic-care pediatric wards, 1153
Cryptococcal antigen, latex agglutination test for diagnosis of disseminated infection with *T. beigelii*, 1167
Cryptococcosis, fatal disseminated, with muscular involvement in an immunosuppressed patient, 567
Cryptosporidiosis, in Northeastern Brazil, 963
Cryptosporidium, asymptomatic intestinal carriage in a patient with AIDS, 195
Cystic fibrosis
  and association of pulmonary disease with infection with *P. aeruginosa*, current knowledge, 575
  IgG proteolytic activity of *P. aeruginosa*, 589
  use of alginate as a protective immunogen against infection, 581
Cytomegaloviral infection
  a serological study of acquisition of infection in families with young children, 948
  and disease, 772
  infant-toddler centers, 953
  lung, in mice, relation of viral replication to interstitial pneumonitis, 454
  sexually transmitted, 344
Cytomegaloviral pneumonia, rapid diagnosis by tissue immunofluoresence, 325
Cytomegalovirus
  excretion in children and natural killer cell activity, 301
  human low-passage, resistance of seropositive volunteers to sc challenge, 737
  murine, monoclonal antibody, for rapid diagnosis by tissue immunofluorescence, 325

DNA hybridization for identification of enterotoxigenic *E. coli* in villages in Thailand, 124
Dane particles, presence of HBV DNA and replicative intermediates, 610
Day care centers, and cytomegaloviral infections, 953
Delta agent
  HBV-associated, prevalence among mentally retarded carriers of HBsAg, 192
  outcome of infection associated with hepatitis B, 925
  infection in a hemodialyzed patient, 374
Diarrhea
  associated with typhoid fever in Bangladesh, 1138
  caused by *C. jejuni*, model of infection in hamsters, 485
  caused by heat-labile, enterotoxigenic bacteria carried gastrointestinally in young children, 114
  in a human, with fever and bacteremia, caused by a novel strain of *E. coli*, 960
  in developing countries
    identification by DNA hybridization of enterotoxigenic *E. coli* in Thai villages, 124
    seroepidemiological studies of El Tor cholera in Bangladesh, 236
  sporadic, associated with cryptosporidiosis in Northeastern Brazil, 963
  traveler's, caused by enteroadherent *E. coli*, 471
Drug abuse, endocarditis caused by *P. aeruginosa* O11 in abusers of pentazocine and tripelennamine, 203, 209

Editorial, vaccine crisis: an emerging societal problem, 981
Editor's choice
  co-factors in disease, 978
  pathogen-insect interactions, analysis, 1175
  variability of antigenicity of influenza A virus, 753
ELISA for diagnosis of visceral leishmaniasis in Kenya, 750
Encephalitis, caused by Japanese encephalitis virus, kinetics of antibody response in human serum and CSF, 1093
Endocarditis
  bacterial, in rats with experimental enterococcal pyelonephritis, 973
  caused by *P. aeruginosa* strain O11 in drug abusers in Chicago, 203
  experimental
    caused by viridans streptococci in animals, treatment with penicillin, 1028
    aortic value, induced by methicillin-resistant *S. aureus*, therapy with vancomycin plus rifampin, 157
    effect on penicillin therapy by exopolysaccharide production by viridans streptococci, 153
Endotoxin, rate of liberation dependent on antibiotic class in therapy for experimental gram-negative bacterial sepsis, 1028
Entamoeba histolytica
  inhibitable adherence lectin associated with mitogenic activity, 816
  partial purification of adherence lectin and relation to virulence, 804
Enteroadherence, as mechanism of pathogenesis in species of *E. coli* causing traveler's diarrhea, 471
Enterococcal pyelonephritis, experimental, and occurrence of bacterial endocarditis in rats, 973
Enterotoxigenic *E. coli*, identified by DNA hybridization in villages in Thailand. 124
Enterotoxigenic bacteria, heat labile, carriage and relation to diarrhea and immune response in young children, 114
Epidemiology
  of *Campylobacter* infections in the U.S., first year, 956
  of antimicrobial agents and *C. difficile* in acute enteric disease in Sweden, 1980–1982, 476
  of influenza A infections
    comparison of illness due to subtypes H1N1 and H3N2, 73
    cross-subtype protection between subtypes H1N1 and H3N2, 81
  of Lyme disease, surveillance study in the United States, 1982, 1144
  of nosocomial, coxsackie B4 virus infections in two chronic-care pediatric wards, 1153
  of RMSF, in Texas, 367
  molecular, of gentamicin-resistance among staphylococci in a cardiac surgery unit, 243
Epiglottitis, mechanisms for development vs. meningitis during

infection with *H. influenzae* type B, 1162
Epstein-Barr virus
co-factor with oncogenes in development of Burkitt's lymphoma, 978
developments in interpretation of serological tests, 984
immunoregulation during acute infection, 1109
infection, long-term serological follow-up after recovery from IM, 1150
infections in homosexual men with chronic, persistent generalized lymphadenopathy, 459
Escherichia coli
a novel strain causing diarrhea, bacteremia, and fever in a human, 960
enteroadherent, as a cause of traveler's diarrhea, 471
enterotoxigenic, as cause of gastrointestinal illness, isolated from imported semisoft cheese, 716
producing Verotoxin, association with idiopathic hemolytic uremic syndrome, 775
strain J5
failure of monoclonal antibodies to core glycolipid to bind to intact smooth strains, 1005
O111, cross-reactive immunoprotective antibodies, 995
prevalence of antibody to the core glycolipid related to age, 988
uropathogenic, association of mannose-resistant hemagglutination and P receptor recognition, 508
Eskimos, Yupik
development of hepatocellular carcinoma in relation to long-term serology of HBV carrier state, 604
investigation of susceptibility to HBV infection, 599

Factor XII–dependent pathways, activation and inhibition in uncomplicated bacteremia or bacterial shock, 1019
Formycin A, in human red blood cells, for treatment of leishmaniasis, 698
Fungal infections, systemic, treatment with liposomal amphotericin B in cancer patients, 704
Fungicidal activity of granulocytes on *C. immitis*, 890

Gastroenteritis
food-borne, involvement of Norwalk virus, 568
pediatriac, caused by adenoviruses, 437
possible etiologic role of human coronavirus, 796
Gastrointestinal illness, caused by enterotoxigenic *E. coli* in imported semisoft cheese, 716
Genetic control of resistance
to *T. rhodesiense* in mice, 911
to toxoplasmosis in mice, 739
Genital infection with HSV, an experimental model, 349
Gentamicin resistance, in coagulase-negative staphylococci in a cardiac surgery unit, 243
Glomerulonephritis, acute poststreptococcal, and the effects of elevated neuraminidase production, 259
Gram-negative bacteremia, detection by limulus amebocyte lysate assay, evaluation in a rat model, 148
Gram-negative bacteria, resistance to amikacin, 295
Gram-negative bacterial sepsis
and antibody to *E. coli* strain J5, dependent on age, 988
role of antibiotic class in the rate of liberation of endotoxin during therapy, 1012

Group B *Streptococcus*
human antibody to the group-specific polysaccharide, 221
of bovine origin, emergence of a multiple beta-lactam resistance phenotype, 494
type II
seroepidemiological studies, 1073
relation of the Ibc protein to opsonization differences between strains, 672
type III infection in neonates, effect of iv immune globulin on susceptibility, 217

HLA specificity
and pathogenesis of infectious diseases, 1
and predisposition for lepromatous leprosy, 9
Haemophilus ducreyi, causing chancroid in outbreak in California, 840
Haemophilus influenzae type b
antibody response to capsular polysaccharide combined with *B. pertussis*, 1174
bacteremia, mechanisms for development of epiglottitis or meningitis, 1162
isolated in Alaska with plasmid-mediated ampicillin resistance, 1061
susceptibility to antibody to LPS associated with serum factors, 869
Haemophilus influenzae, nontypable, reinfection in chinchillas, 273
Hageman factor–dependent pathways, activation and inhibition in uncomplicated bacteremia or bacterial shock, 1019
Hantaan virus infection, protection mediated by spleen cells in infant mice, 691
Health care personnel, attitudes and behavior to influenza vaccine, 1170
Hematoporphyrin derivative, in photoradiation therapy, bactericidal effects, 166
Hemodialysis, risk for delta infection, 374
Hemolytic uremic syndrome, idiopathic, association with infection with Verotoxin-producing *E. coli*, 775
Hepatitis
chronic active, outcome associated with HBV infection superinfected with delta agent, 926
non-A, non-B, possible multiple blood-borne strains, 618
Hepatitis A virus, origin of the HM175 strain, 365
Hepatitis B
acquisition by a mentally retarded community student, 741
acute, relation of age to progress of disease and development of carrier state, 599
associated delta agent infection
prevalence among mentally retarded carriers of HBsAg, 192
outcome, 925
asymptomatic carriers, long-term serology and development of primary hepatocellular carcinoma, 604
prevention of perinatal transmission of virus
by vaccination in Japan, 287
comparison of immunization methods in Korea, 280
surface antigen carrier state
association with hepatocellular carcinoma and viral DNA, 1081
in the mentally retarded, prevalence of delta agent, 192
subsequent to infection and in relation to age and progress of disease, 599

virus subtype as an identifier of source of infection, 741
vaccine, response in children whose parents have hepatocellular carcinoma, 187
Hepatitis B virus DNA
in infected liver and hepatocellular carcinoma, 1081
in Dane particles and presence of replicative intermediates, 610
Hepatocellular carcinoma
association of presence of HBV DNA and the carrier state, 1081
development in relation to long-term serology of HBV carrier state, 604
primary, response to HBV vaccine of children of patients, 187
Herpes simplex virus
genital, an experimental model for activation, 349
IgG subclass antibodies, 929
lesions, treatment with topical acyclovir for immunocompromised patients, 970. 971
synergistic effect of combinations of antiviral agents in microtiter plate assay, 1116
replication in human T cells stimulated with interleukin-2, 544
transference on fomites, 746
type 1, experimental infection, IgG-mediated viral clearance, 464
type 2, thymidine kinase mutants, infections with, 548
Herpes zoster in ambulatory patients, adverse effects of high-dose iv acyclovir, 362
Herpesvirus infections
high-dose oral acyclovir for immunosuppressed children as protection against disseminated disease, 372
VZV infection of strain 2 guinea pigs as an animal model, 106
Heterotypic immunity to influenza A virus subtypes H1N1 and H3N2, 81
Homosexual men
two new species of *Campylobacter* associated with enteric disease, 131
with chronic, persistent generalized lymphadenopathy, presence of EBV infections, 459
Houston Family Study, comparison of illness due to influenza A subtypes H1N1 and H3N2, 73

Immune globulin, iv,
comparison of activity with method of preparation, 1171
effect on phagocytosis of group B streptococcus in neonatal serum, 217
Immune response
changes after treatment of schistosomiasis with praziquantel, 320
defective, in disseminated coccidioidomycosis, 314
human antibody to the group-specific polysaccharide of group B *Streptococcus*, 211
resistance of seropositive volunteers to sc challenge with low-passage human cytomegalovirus, 737
to experimental infection with HSV type 1, IgG-mediated viral clearance, 464
to disease, and HLA specificity, 1
to heat-labile, enterotoxigenic bacteria carried gastrointestinally in young children, 114
to influenza A by viral antigen expression of cell surfaces, 308
to neisserial antigen H.8, possible potential for vaccine against *N. gonorrhoeae* and *N. meningitidis*, 650
to vaccination with live Ty21a *S. typhi* vaccine, demonstration of specific IgA in human feces, 482
Immunization
against HBV, for prevention of perinatal transmission of virus, 287
against rubella, failed, in adults and associated with immune response, 330
methods, comparison in the prevention of perinatal transmission of HBV in Korea, 280
to *P. aeruginosa* exotoxoid, responses in adult volunteers, 375
with alginate, as protection against infection with *P. aeruginosa*, 581
Immunocompromised hosts
infections caused by *Capnocytophaga*, 140
test for cryptococcal antigen in diagnosis of disseminated infection with *T. beigelii*, 1167
use of topical acyclovir on herpes simplex lesions, 970, 971
Immunoglobin G
subclass antibodies in response to a 14-valent pneumococcal vaccine in the elderly, 845
subclass antibodies to HSV, 929
to group-specific polysaccharide of group B streptococcus in humans, 221
Immunoglobulin M–specific immunofluorescence assay for detection of RMSF in Kansas, 369
Infant-toddler centers, cytomegaloviral infections, 953
Infectious mononucleosis
immunoregulation during acute infection with EBV, 1109
long-term serological follow-up after recovery from infection, 1150
Inflammatory response in experimental pneumococcal meningitis, relative to roles of bacterial cell walls and capsule, 535
Influenza
induction of immunity by a reassortant influenza A virus, 744
vaccine, attitudes and behavior of health care personnel, 1170
Influenza A/Hong Kong/123/77 (H1N1), resistance to challenge induced by exposure to another influenza A virus, 744
Influenza A virus
effect of in vitro infection on human lymphocytes, monocytes, and macrophages, 308
subtypes H1N1 and H3N2, comparison of infection rates and severity of illness, 73
subtypes H1N1 and H3N2, cross-subtype protection in humans, 81
treatment of infection with amantidine in the USA, 1977–1982, 372
variability of antigenicity, 753
Insect-pathogen interactions, analysis of vector functions, 1175
Interferon
alpha$_2$, intranasal, for prophylaxis of natural respiratory virus infection, 731
circulating levels in Colorado tick fever, 966
dynamics during acute infection with EBV, 1109
human recombinant, and nucleosides, synergistic effect against HSV in microtiter plate assay, 1116
treatment of poliomyelitis, 745
Interleukin-1, induction by TSST-1, 514

Interleukin-2
production by rat lymph nodes stimulated with *M. pulmonis* membranes, 541
stimulation of human T cells, and consequent HSV replication, 544
Interstitial pneumonitis, relation to viral replication in murine cytomegaloviral lung infection, 454
Intravenous drug abusers, with nonopportunistic infections, reversal of T cell helper/suppressor ratios, 748
Intravenous immune globulin, comparison of activity with method of preparation, 1171
Iron, differential effects on the growth of *L. monocytogenes*, 721

J5 strain of *E. coli*
antibody prevalence dependent on age, 988
cross-reactive immunoprotective antibodies, 995
monoclonal antibodies to core glycolipid fail to bind intact smooth cells, 1005
Japanese encephalitis virus, kinetics of antibody responses in human serum and CSF, 1093

Ketaconazole, effect on amphotericin B prophylaxis for disseminated aspergillosis, 902
Klebsiella pneumoniae K1 capsular polysaccharide vaccine, safety and immunogenicity for humans, 665
Klebsiella polysaccharide, as inducer of increased antibody responses to pneumococcal type 19F polysaccharide, 658

Laboratory animals, prevalence of *C. jejuni* in random-source cats used for biomedical research, 743
Legionella pneumophila
definition of subtypes by monoclonal antibodies, 976
toxin, effect on PMNL oxidative metabolism, 42
Leishmania, activity of human red blood cells containing formycin A, 698
Leishmaniasis, visceral, ELISA for diagnosis in Kenya, 750
Leprosy, lepromatous, predisposition controlled by HLA specificities, 9
Leukemia, hairy cell, humoral response of patients to disseminated infection with *M. avium–M. intracellulare*, 523
Leukopenia, virus-induced, Colorado tick fever as a human model, 449
Limulus amebocyte lysate assay, for detection of gram-negative bacteremia, evaluation in a rat model, 148
Liposomal amphotericin B, for the treatment of systemic fungal infections in cancer patients, 704
Liposomal ampicillin, compared with free drug, for treatment of infection with *L. monocytogenes*, 917
Listeria monocytogenes
effect of iron on growth, 721
treatment with liposome-entrapped or free ampicillin in mice, 917
Lung antibacterial defenses, isolation of an antibacterial peptide from human lung lavage fluid, 1123
Lyme disease, surveillance in the United States, 1982, 1144
Lymphadenopathy syndrome, patients with disproportionate expansion of a minor subset of T cells, 555
Lymphadenopathy, chronic, persistent generalized, in homosexual men, caused by EBV, 459
Lymphocyte proliferation, induced by toxic-shock-syndrome toxin-1, comparison of murine, human, and rabbit cell responses, 65
Lymphoid atrophy, systemic, in mice with infections with coxsackievirus B3, 1100

Macrophages, monocyte-derived, in phagocytosis of *B. dermatitidis*, 57
Magnesium ion control of production of TSST-1, 1158
Malnutrition, maternal, influence in suckling rats, 23
Mannose-resistance in uropathogenic *E. coli*, associated with P receptor recognition, 508
Meningitis
differentiated from other CNS diseases by determination of C-reactive protein in CSF, 854
induction of inflammation by components of pneumococcal cell wall, 859
mechanisms for development vs. epiglottitis during infection with *H. influenzae* type B, 1162
Methicillin-resistant *S. aureus* as a causative agent of experimental aortic valve endocarditis, 157
Metronidazole, action on facultative anaerobes, 569
Microbial resistance to new beta-lactam antibiotics, clinical and laboratory implications, 399
Microbicidal effect, of human serum on *Campylobacter* isolates, 227
Microbicidal function
of neutrophils
against *N. asteroides*, 47
in the phagocytosis of *N. gonorrhoeae*, 33
influence of drugs that block calcium channels, 15
of PMNLs, defective triggering by *L. pneumophila* toxin, 42
Microbicidal response, evoked by *B. dermatitidis*, 57
Molluscum contagiosum, as a sexually transmitted disease, 376
Monoclonal antibodies
for definition of subtypes of *L. pneumophila*, 976
in antigenic characterization of RSV, 626
to core glycolipid of *E. coli* J5, failure to bind intact smooth cells, 1005
to *R. rickettsii*, characterization of protection in mice, 1052
Murine cytomegaloviral interstitial pneumonitis, relation of viral replication to interstitial pneumonitis, 454
Mycobacterium, cross-reaction of cytoplasm and cell-wall antigens with those of corynebacterium, 170
Mycobacterium leprae, HLA-linked control of predisposition to lepromatous leprosy, 9
Mycobacterium avium–Mycobacterium intracellulare
humoral response to disseminated infection in specific groups of patients, 523
in the intestinal tract of patients with AIDS, 179
Mycoplasma pneumoniae infection, point-source outbreak in a family unit, 186
Mycoplasma pulmonis membranes, for stimulation of rat lymph node cells to produce interleukin-2, 541

Natural killer cells, activity in children excreting CMV, 301
Necrotizing enteritis, associated with toxigenic type A *C. perfringens* infection, 974
Neisseria gonorrhoeae
immunogenicity of neisserial antigen H.8 in disseminanted infection, 650
phagocytosis by neutrophils, influence of serum factors on

different strains, 33
Neisseria meningitidis
immunogenicity of neisserial antigen H.8 in disseminated infection, 650
persistence after iv antibiotic therapy, 370
Neisseria mucosa, causative agent of visceral botryomycosis in a patient with chronic granulomatous disease, 563
Neonatal HBV infection
efficacy of immunization in Korea, 280
prevention by immunization in Japan, 287
Neonatal protein deprivation, influence in the suckling rat model, 23
Neuraminidase production, by streptococci from patients with glomerulonephritis, 259
Neutropenic patients, risks of therapy with TMP-SMZ, 969
Neutrophil function
human
influence of calcium channel–blocking drugs on their microbicidal function, 15
phagocytosis of *N. gonorrhoeae*, 33
in inhibition of *N. asteroides*, 47
influenced by maternal protein deprivation in suckling rats, 23
Nocardia asteroides
inhibition by neutrophils, 47
two immunodominant antigens as mediators of antibody response, 895
Nocardiosis, antibody response mediated by two immunodominant antigens, 895
Non-A, non-B hepatitis, possible multiple blood-borne strains, 618
Norwalk virus
and involvement in food-borne outbreaks of gastroenteritis, 568
immunity, naturally acquired on two remote Panamanian islands, 99
Nosocomial spread of coxsackie B4 virus infection in two chronic-care pediatric wards, 1153
Nucleosides, with HuIFN, synergistic effect against HSV in microtiter plate assay, 1116

Opsonization differences between strains of type II group B *Streptococcus*, relation of Ibc protein, 672
Opsonization, requirements in interaction of *C. trachomatis* with PMNLs, 1045
Opsonophagocytosis of different strains of *N. gonorrhoeae*, 33
Osteomyelitis, experimental, caused by *P. aeruginosa*, treated with ciprofloxacin, 291
Otitis media
acute, identification of respiratory virus antigens in middle ear fluids, 444
due to nontypable *H. influenzae* and response to reinfection, 273
Otitis, invasive external, caused by *A. fumigatus* in an immunocompromised patient, 196
Outer membrane antigens, role in modification of response to rechallenge with nontypable *H. influenzae*, 273
Outer membrane proteins, changes in composition related to antibiotic cross-resistance, 501

P receptor recognition in uropathogenic *E. coli*, associated with mannose resistance, 508
Panama, study of naturally acquired immunity to rotavirus and Norwalk virus on two remote islands, 99
Pediatric gastroenteritis, caused by adenoviruses, 437
Pediatrics, a crisis in breakdown of vaccination programs, 981
Penicillin therapy of experimental endocarditis
caused by viridans streptococci in animals, 1028
effects of exopolysaccharide production by viridans streptococci, 153
Pentazocine and tripelennamine abusers
in Chicago, outbreak of endocarditis caused by *P. aeruginosa* O11, 203
growth of *P. aeruginosa* O11 in cultures with the drugs, 209
Peripheral joints of humans, as environment for persistent rubella virus, 638
Perspective
anti-idiotypic antibodies and infectious disease, 761
cytomegaloviral infection and disease, 772
Epstein-Barr virus, developments in interpretation of serological tests, 984
HLA complex and pathogenesis of infectious diseases, 1
Pseudomonas aeruginosa associated with cystic fibrosis, 575
the role of Shiga toxin in infectious disease, 766
Pertussis toxin, neutralizing antibodies in whooping cough, 646
Phagocytosis, of *C. immitis* mediated by cationic peptides, 890
Photoradiation therapy with hematoporphyrin derivative, bactericidal effects, 166
Picornaviruses, coxsackievirus B3 infection in mice, causing systemic lymphoid atrophy, 1100
Plasmid-mediated resistance
to antimicrobial agents: spread of resistance to trimethoprim in Enterobacteriaceae, 783
to ampicillin in *H. influenzae* type b isolates from Alaska, 1061
to gentamicin in coagulase-negative staphylococci, 243
to multiple drugs in *S. enteritidis* outbreak in Liberia, 790
Plasmids coding for virulence in *S. typhi* from Chile and Thailand, 551
Pneumococcal meningitis, experimental
effect of ampicillin and corticosteroids on CSF characteristics, 528
induction of inflammation and relative roles of the bacterial cell wall and capsule, 535
Pneumococcal type 19F polysaccharide, antibody response magnified by coadministration of klebsiella polysaccharide, 658
Pneumococcal polysaccharide vaccine
14-valent, specific IgG-class responses in the elderly, 845
23-valent, responses in volunteers, 749
Pneumocystis carinii attachment to rat lung, examination of ultrastructure, 181
Pneumonia
caused by *P. carinii*, attachment examined in rat lung, 181
in calves, effect of bovine herpesvirus-1 on immunologic functions, 937
mild, epidemic caused by an unusual strain of *C. psittaci*, 832
Poliomyelitis, treatment with interferon, 745
Poliovirus vaccine, oral, history of its development and use, 420
Polymorphonuclear leukocytes
defective triggering of oxidative metabolism by *L. pneumophila* toxin, 42
human, phagocytosis and killing of *Brucella* species, 682

interaction with *C. trachomatis*, 1045
Polyurethane dressings, association with local infection of cannulae wounds, 971
Praziquantel
effect on immune responses after treatment for schistosomiasis, 320
effects on different developmental stages of *S. mansoni* in vitro and in vivo, 1130
Presidential address from annual meeting of IDSA, 383
Protein deprivation, maternal, influence on nutritional status and neutrophil function of suckling rats, 23
Pseudomonas aeruginosa
as cause of experimental osteomyelitis, treated with ciprofloxacin, 291
associated with pulmonary disease in cystic fibrosis, current knowledge, 575
exotoxoid-A, vaccine, responses in adult volunteers, 375
IgG proteolytic activity in cystic fibrosis, 589
O11, survival in pentazocine and tripelennamine, 209
proteolytic activity against IgG in patients with cystic fibrosis, 589
serotype O11 causing endocarditis in drug abusers in Chicago, 203
use of alginate as a protective immunogen against infection, 581
Pulmonary antibacterial defense, isolation of an antibacterial peptide from human lung lavage fluid, 1123

Rapid diagnosis of CMV pneumonia by tissue immunofluorescence, 325
Rectal biopsy specimen, isolation of *C. jejuni* from patient with acute diarrhea, 976
Red blood cells, human, containing formycin A, antileishmanial activity, 698
Respiratory syncytial virus
antigenic analysis of a putative new strain, 634
antigenic characterization with monoclonal antibodies, 626
antigens, identification in middle ear fluids of children with acute otitis media, 444
Rickettsia conorii, persistence of antibodies after acute Boutonneuse fever, 377
Rickettsia rickettsii
antibodies, prevalence in an area endemic for Rocky Mountain spotted fever, 823
characterization of protective monoclonal antibodies in mice, 1052
Rifampin plus vancomycin, in treatment of experimental aortic-valve endocarditis, 157
Rocky Mountain spotted fever
characterization of protective monoclonal antibodies in mice, 1052
IgM-specific IFA for diagnosis in Kansas, 369
prevalence of antibodies to *R. rickettsii* in an endemic area, 823
serological evidence of subclinical infection in Texas, 367
Rotaviral infection
and immunobiological failures, 569
immunity, naturally acquired on two remote Panamanian islands, 99
Rubella
immunization, failed, in adults and investigation of their immune responses, 330
vaccines, comparative study of antibodies in serum and nasopharyngeal washings, 89
virus infection, persistent, in human synovial cells in vitro, 638

Salmonella enteritidis, outbreak in multiple drug-resistant Liberia, 790
Salmonella paratyphi A infection, and associated diarrhea in Bangladesh, 1138
Salmonella typhi
Ty21a vaccine, live, specific IgA in human feces after immunization, 482
infection, and associated diarrhea in Bangladesh, 1138
infections in Chile and Thailand, survey of plasmids, 551
Salmonella typhimurium bacteremia in mice, influence on course of infection with *S. mansoni*, 1116
Schistosoma mansoni
changes in immune response after treatment of human infection, 320
effects of praziquantel on different developmental stages in vitro and in vivo, 1130
infection, influence of bacteremia with *S. typhimurium* on the survival of mice, 1116
Schistosomiasis
hepatosplenic, study of association with salmonella bacteremia, 1116
treatment with praziquantel and effect of drug on different developmental stages, 1130
Serological testing for Epstein-Barr virus, developments in interpretation, 984
Serum factor-dependent resistance of *H. influenzae* type b to antibody to LPS, 869
Sexually transmitted disease
chancroid outbreak in California, 840
CMV infection, 344
molluscum contagiosum, 376
Shiga toxin
role in the pathogenesis of infectious diseases, 766
produced in *E. coli*, infection associated with idiopathic hemolytic uremic syndrome, 775
Shigella species, ionic, hydrophobic, and hemagglutinating properties, 194
Sleeping sickness, genetic control of resistance in mice, 911
Staphylococcus aureus that produce toxic-shock-syndrome toxin, association of tryptophan auxotypy, 1157
Streptococcus
beta-hemolytic, and production of neuraminidase, 259
group B, type II, seroepidemiological studies, 1073
Streptococcus agalactiae, emergence of a resistance phenotype for multiple beta-lactams, 494
Streptococcus pneumoniae
components of cell wall as inducers of meningeal inflammation, 859
experimental meningitis
effect of ampicillin and corticosteroids on CSF characteristics, 528
relative roles of bacterial cell wall and capsule, 535
laboratory diagnosis, 378
vaccine, responses of volunteers to
a 14-valent pneumococcal polysaccharide vaccine, specific

IgG responses in the elderly, 845
a 23-valent pneumococcalpolysaccharide vaccine, 749
Syphilis, appearance of IgG and IgM during infection in humans, 264

T cell
human, stimulated with interleukin 2 and consequent HSV replication, 544
ratios, reversal of helper/suppressor cell ratios in iv drug abusers with nonopportunistic infections, 748
response, defective, in disseminated coccidioidomycosis, 314
subset, minor, expansion in patients with AIDS and lymphadenopathy syndrome, 555
viruses, detected in cultured lymphocytes of a hemophiliac with AIDS, 559
Tetanus antitoxin titers, in diverse populations of women of childbearing age, 850
Thymidine kinase mutants of HSV type 2, infections with, 548
Tobramycin vs. ciprofloxacin, for treatment of experimental osteomyelitis caused by *P. aeruginosa*, 291
Toxic shock syndrome
control of TSST-1 production by magnesium ion, 1158
development of antibodies to the toxin, 883
Toxic-shock-syndrome toxin
production in *S. aureus* and association of tryptophan auxotypy, 1157
development of antibody in patients with toxic shock syndrome, 883
Toxic-shock-syndrome toxin-1
control of production by magnesium ion, 1158
induction of human interleukin-1, 514
induction of human, murine, and rabbit lymphocyte proliferation, 65
Toxoplasma gondii, murine infection, resistance mediated by the H-2 complex, 739
Toxoplasmosis, murine, H-2 complex–linked resistance, 739
Trachoma
caused by *C. trachomatis* immunotype J in a previously endemic area, 1034
similar strains of *C. trachomatis* causing genital and ocular infections, 1034
Treponema pallidum, antigens, recognition by IgG and IgM in humans, 264
Trichosporon beigelii
causing fatal fungemia with arthritic involvement in a bone marrow transplant recipient, 566
disseminated infections, diagnosis with latex agglutination test for cryptococcal antigen, 1167
Trimethoprim resistance in Enterobacteriaceae, spread by a single plasmid, 783
Trimethoprim-sulfamethoxazole, potential risks of therapy in neutropenic patients, 969
Tripelennamine and pentazocine abusers
growth of *P. aeruginosa* O11 in cultures with the drugs, 209
in Chicago, outbreak of endocarditis caused by *P. aeruginosa* O11, 203
Trypanosoma rhodesiense, genetic control of natural resistance, 911
Trypanosomiasis, genetic control of resistance in mice, 911
Tryptophan auxotypy, associated with production of toxic-shock-syndrome toxin in *S. aureus*, 1157
Typhoid fever, association with diarrhea in Bangladesh, 1138

Ultrastructural studies of release of *C. trachomatis* from HeLa 229 cells, 1037

Vaccination
a crisis in vaccination programs, 981
against influenza, attitudes and behavior of health care personnel, 1170
with 14-valent pneumococcal vaccine in the elderly, specific IgG-class responses, 845
with live Ty21a *S. typhi*, demonstration of specific IgA in human feces, 482
Vaccines
based on anti-idiotypic antibodies, implication for infectious diseases, 761
K. pneumoniae K1 capsular polysaccharide, evaluation in humans, 665
new directions in development and use, 407
Vancomycin plus rifampin, in treatment of experimental aortic-valve endocarditis, 157
Varicella-zoster, virus infection in strain 2 guinea pigs, a model for infection, 106
Verotoxin, role in the pathogenesis of infectious diseases, 766
Verotoxin-producing *E. coli*, infection associated with idiopathic hemolytic uremic syndrome, 775
Vibrio cholerae O1, and serum antibody levels in Bangladesh, 236
Viral DNA, HBV, association with HBV carrier state and hepatocellular carcinoma, 1081
Viral antigen expression, in cells after in vitro infection with influenza A simplex virus, 308
Viral clearance, IgG-mediated, of an experimental infection with herpes simplex virus type 1, 464
Viridans streptococci
causing experimental endocarditis in animals, treatment with penicillin therapy, 1028
effect of exopolysaccharide production on penicillin therapy of experimental endocarditis, 153
Virus-induced leukopenia, Colorado tick fever as a human model, 449

Whooping cough, neutralizing antibodies to pertussis toxin, 646